Poll: 1 in 8 Adults Say They’ve Taken a GLP-1 Drug, Including 4 in 10 of Those with Diabetes and 1 in 4 of Those with Heart Disease May 10, 2024 News Release About one in eight adults (12%) say they have taken one of an increasingly popular class of prescription drugs known as GLP-1s that are used for weight loss and to treat diabetes and reduce the risk of heart disease and stroke, a new KFF Health Tracking Poll finds. This includes…
KFF Health Misinformation Monitor Volume 3 July 11, 2024 Page This edition focuses on intentionally false or misleading information online and its potential impact on public trust in health care. We share a recent report that exposed a covert U.S. military social media disinformation campaign in the Philippines that may have undermined public confidence in vaccines. We also examine how false claims about sunscreen and non-FDA-approved “miracle cures” may be discouraging people from taking important preventative measures and seeking legitimate medical treatment. Finally, we explore the rise of counterfeit diabetes and weight-loss drugs like Ozempic and the potential impact on trust in the pharmaceutical supply chain.
10 Key Facts About Women with Medicare April 30, 2024 Issue Brief This brief examines 10 key facts about women with Medicare and presents new statistics on the health, economic and functional status of women with Medicare.
Key Data on Health and Health Care by Race and Ethnicity June 11, 2024 Page This analysis examines how people of color fare compared to White people across 64 measures of health, health care, and social determinants of health using the most recent data available from federal surveys and administrative sets as well as the 2023 KFF Survey on Racism, Discrimination, and Health.
International Comparison of Health Systems May 28, 2024 Page This Health Policy 101 chapter explores the performance of the U.S. health system on a number of cost, outcomes, and quality measures by comparing it with those in similarly large and wealthy OECD nations. It highlights that despite significant spending, Americans have shorter life expectancies and encounter more barriers to health care, influenced by both the health system’s structure and broader socioeconomic factors.
KFF Health Misinformation Monitor Volume 2 June 27, 2024 Page This issue of the Monitor focuses on recent Supreme Court decisions impacting health misinformation. We examine cases balancing free speech and platform regulation, the Court’s ruling on mifepristone access and public perceptions of social media moderation. We also explore COVID-19 narratives after Dr. Fauci’s congressional testimony and AI developments in predicting misinformation trends during pandemics.
A New Use for Wegovy Opens the Door to Medicare Coverage for Millions of People with Obesity April 24, 2024 Issue Brief The FDA recently approved a new use for Wegovy, the blockbuster anti-obesity drug, to reduce the risk of heart attacks and stroke in people with cardiovascular disease who are overweight or obese – a decision that opens the door to Medicare coverage of Wegovy, which is prohibited by law from covering drugs used for obesity. This brief analyses how many Medicare beneficiaries could be eligible for the new use of Wegovy and the potential impact on Medicare spending.